section name header

Evidence summaries

Nsaids and Blood Pressure

NSAIDs may elevate blood pressure and antagonise blood pressure lowering effect of antihypertensive medication, but the effects may differ between agents. Level of evidence: "C"

The quality of evidence is downgraded by study limitations, and by inconsistency (variability in results).

Summary

A systematic review 1 included 38 randomised, placebo-controlled trials, and 12 randomised but not placebo-controlled studies. NSAIDs elevated supine mean blood pressure by 5.0 mmHg (95% CI 1.2 to 8.7 mmHg), NSAIDs had no significant effect on weight, creatinine clearance, plasma renin activity or daily urinary excretion of sodium and prostaglandins. NSAIDs antagonised the antihypertensive effect of beta-blockers (blood pressure elevation, 6.2 mmmHg, 95% CI 1.1 to 11.4 mmHg) more than they did that of vasodilators and diuretics. Among NSAIDs piroxicam produced the most marked elevation in blood pressure (6.2 mmHg, 95% CI 0.8 to 11.5). Sulindac and aspirin had the least hypertensive effect.

A double-blind, randomized, multicentre non-inferiority cardiovascular-safety trial (PRECISION-ABPM, a substudy of PRECISION) 2 included 444 subjects with osteoarthritis (92%) or rheumatoid arthritis (8%) who had pre-existing or were at relatively high risk for cardiovascular disease. Sixty-two percent of the patients were treated with ACE inhibitors or ARBs, 35% with a diuretic and 22% with a calcium channel blocker, while 53% received multiple antihypertensive therapies. There were 146 patients assigned to celecoxib (mean daily dose 208+/-34 mg), 147 to naproxen (852+/-98 mg), and 151 to ibuprofen (2031+/-237 mg). The changes in mean 24-h systolic blood pressure (SBP) after 4 months were: celecoxib -0.3 mmHg (95% CI -2.25 to 1.74); ibuprofen 3.7 mmHg (95% CI 1.72 to 5.58), and naproxen-treated patients 1.6 mmHg (95% CI -0.40 to 3.57). These changes resulted in a difference of -3.9 mmHg (p=0.0009) between celecoxib and ibuprofen, of -1.8 mmHg (p=0.12) between celecoxib and naproxen, and of -2.1 mmHg (p=0.08) between naproxen and ibuprofen.

Comment:The European Medicines Agency (EMEA) has ompleted a review of the benefits and risks of etoricoxib-containing medicines http://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib#key-facts-section. Doctors should not prescribe etoricoxib-containing medicines to patients whoseblood pressure is persistently above 140/90 mmHg and has not been adequately controlled. Blood pressure should be monitored for 2 weeks after a patient starts to take etoricoxib and regularly thereafter.

The following decision support rules contain links to this evidence summary:

References

Primary/Secondary Keywords